FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness.

Vanda Pharmaceuticals announced that the FDA has lifted the partial clinical hold on tradipitant for motion sickness treatment. The lift followed a formal dispute resolution request and an expedited re-review by CDER leadership under a collaborative framework established between Vanda and the FDA in October 2025. The FDA agreed that motion sickness is an acute, self-limiting condition, making tradipitant an appropriate treatment option.